| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| VRDNViridian Therapeutics, Inc. | 3.15B | 33.03 | -8.30 | -3.82% | -426.58% | -60.04% | 0.03 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 2.54M | 3.34M | 4M | 8.39M | 4.46M | 1.05M | 2.96M | 1.77M | 314K | 302K |
| Revenue Growth % | -0.41% | 0.31% | 0.2% | 1.09% | -0.47% | -0.76% | 1.82% | -0.4% | -0.82% | -0.04% |
| Cost of Goods Sold | 2.47M | 2.55M | 19.62M | 30.42M | 0 | 28.3M | 0 | 0 | 0 | 0 |
| COGS % of Revenue | 0.97% | 0.76% | 4.9% | 3.63% | - | 26.96% | - | - | - | - |
| Gross Profit | 66K | 789K | -15.62M | -22.04M | 4.46M | -27.25M | 2.96M | 1.77M | 314K | 302K |
| Gross Margin % | 0.03% | 0.24% | -3.9% | -2.63% | 1% | -25.96% | 1% | 1% | 1% | 1% |
| Gross Profit Growth % | -0.94% | 10.95% | -20.8% | -0.41% | 1.2% | -7.11% | 1.11% | -0.4% | -0.82% | -0.04% |
| Operating Expenses | 11.25M | 10.46M | 30.54M | 41.47M | 46.44M | 83.13M | 82.69M | 136.08M | 254.76M | 299.34M |
| OpEx % of Revenue | 4.43% | 3.14% | 7.63% | 4.95% | 10.41% | 79.17% | 27.91% | 76.79% | 811.35% | 991.18% |
| Selling, General & Admin | 10.25M | 9.57M | 10.91M | 11.05M | 11.65M | 13.27M | 25.8M | 35.18M | 95M | 61.08M |
| SG&A % of Revenue | 4.04% | 2.87% | 2.73% | 1.32% | 2.61% | 12.63% | 8.71% | 19.85% | 302.54% | 202.26% |
| Research & Development | 1M | 888K | 19.62M | 30.42M | 34.79M | 28.3M | 56.89M | 100.89M | 159.76M | 238.25M |
| R&D % of Revenue | 0.39% | 0.27% | 4.9% | 3.63% | 7.8% | 26.96% | 19.2% | 56.94% | 508.81% | 788.92% |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 41.56M | 0 | 0 | 0 | 0 |
| Operating Income | -11.19M | -12.51M | -26.53M | -33.08M | -41.98M | -110.38M | -79.73M | -134.3M | -254.45M | -299.04M |
| Operating Margin % | -4.41% | -3.75% | -6.63% | -3.95% | -9.41% | -105.12% | -26.91% | -75.79% | -810.35% | -990.18% |
| Operating Income Growth % | -0.63% | -0.12% | -1.12% | -0.25% | -0.27% | -1.63% | 0.28% | -0.68% | -0.89% | -0.18% |
| EBITDA | -11M | -12.17M | -26.22M | -32.8M | -41.69M | -110.14M | -79.61M | -134.05M | -253.93M | -297.8M |
| EBITDA Margin % | -4.34% | -3.65% | -6.55% | -3.91% | -9.35% | -104.9% | -26.87% | -75.65% | -808.69% | -986.08% |
| EBITDA Growth % | -0.64% | -0.11% | -1.16% | -0.25% | -0.27% | -1.64% | 0.28% | -0.68% | -0.89% | -0.17% |
| D&A (Non-Cash Add-back) | 184K | 341K | 308K | 281K | 288K | 239K | 120K | 255K | 522K | 1.24M |
| EBIT | -11.19M | -12.58M | -26.13M | -31.83M | -41.04M | -40.52M | -79.41M | -129.39M | -235.89M | -266.9M |
| Net Interest Income | -141K | -95K | 20K | 381K | 106K | -335K | 315K | 4.43M | 16.72M | 29.09M |
| Interest Income | 0 | 0 | 403K | 1.25M | 941K | 173K | 318K | 4.92M | 18.56M | 32.13M |
| Interest Expense | 141K | 95K | 383K | 873K | 835K | 508K | 3K | 486K | 1.85M | 3.05M |
| Other Income/Expense | -141K | -166K | 20K | 381K | 106K | -335K | 315K | 4.43M | 16.72M | 29.09M |
| Pretax Income | -11.33M | -12.67M | -26.51M | -32.7M | -41.87M | -110.72M | -79.41M | -129.87M | -237.73M | -269.95M |
| Pretax Margin % | -4.46% | -3.8% | -6.62% | -3.9% | -9.39% | -105.44% | -26.8% | -73.29% | -757.11% | -893.87% |
| Income Tax | 0 | 95K | 95K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -11.33M | -12.67M | -26.51M | -32.7M | -41.87M | -110.72M | -79.41M | -129.87M | -237.73M | -269.95M |
| Net Margin % | -4.46% | -3.8% | -6.62% | -3.9% | -9.39% | -105.44% | -26.8% | -73.29% | -757.11% | -893.87% |
| Net Income Growth % | -0.44% | -0.12% | -1.09% | -0.23% | -0.28% | -1.64% | 0.28% | -0.64% | -0.83% | -0.14% |
| Net Income (Continuing) | -11.33M | -12.67M | -26.51M | -32.7M | -41.87M | -110.72M | -79.41M | -129.87M | -237.73M | -269.95M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -21.00 | -17.57 | -20.66 | -16.57 | -20.31 | -31.20 | -6.66 | -3.91 | -5.31 | -3.98 |
| EPS Growth % | 0.6% | 0.16% | -0.18% | 0.2% | -0.23% | -0.54% | 0.79% | 0.41% | -0.36% | 0.25% |
| EPS (Basic) | -21.00 | -17.57 | -20.66 | -16.57 | -20.31 | -31.20 | -6.66 | -3.91 | -5.31 | -3.98 |
| Diluted Shares Outstanding | 539.46K | 721.41K | 1.28M | 1.97M | 2.09M | 3.56M | 11.92M | 32.09M | 44.76M | 67.89M |
| Basic Shares Outstanding | 539.45K | 721.41K | 1.28M | 1.97M | 2.09M | 3.56M | 11.92M | 32.09M | 44.76M | 67.89M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 11.73M | 4.26M | 51.87M | 65.37M | 29.74M | 129.61M | 200.16M | 424.55M | 486.48M | 738.46M |
| Cash & Short-Term Investments | 10.83M | 3.34M | 47.44M | 62.48M | 26.84M | 127.64M | 196.97M | 424.55M | 477.37M | 717.58M |
| Cash Only | 10.83M | 3.34M | 47.44M | 32.61M | 24.85M | 45.9M | 42.3M | 155.58M | 102.83M | 99.59M |
| Short-Term Investments | 0 | 0 | 0 | 29.88M | 2M | 81.74M | 154.67M | 268.97M | 374.54M | 617.99M |
| Accounts Receivable | 394K | 524K | 1.46M | 24K | 108K | 0 | 451K | 102K | 102K | 0 |
| Days Sales Outstanding | 56.66 | 57.31 | 132.76 | 1.04 | 8.84 | - | 55.56 | 21.01 | 118.57 | - |
| Inventory | 187K | 64K | 0 | 0 | 0 | 0 | 0 | -6.62M | 0 | 0 |
| Days Inventory Outstanding | 27.61 | 9.17 | - | - | - | - | - | - | - | - |
| Other Current Assets | 321K | 170K | 2.97M | 2.87M | -108K | 0 | 0 | 6.52M | 9.01M | 20.88M |
| Total Non-Current Assets | 1.17M | 883K | 613K | 777K | 523K | 1.64M | 3.55M | 10.54M | 3.95M | 3.94M |
| Property, Plant & Equipment | 1.15M | 625K | 563K | 727K | 523K | 787K | 2.06M | 2.94M | 3.34M | 3.44M |
| Fixed Asset Turnover | 2.20x | 5.34x | 7.11x | 11.54x | 8.53x | 1.33x | 1.44x | 0.60x | 0.09x | 0.09x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 15K | 258K | 50K | 50K | 0 | 857K | 1.49M | 7.61M | 604K | 501K |
| Total Assets | 12.9M | 4.26M | 52.48M | 66.15M | 30.26M | 131.25M | 203.71M | 435.09M | 490.42M | 742.4M |
| Asset Turnover | 0.20x | 0.78x | 0.08x | 0.13x | 0.15x | 0.01x | 0.01x | 0.00x | 0.00x | 0.00x |
| Asset Growth % | 0.6% | -0.67% | 11.32% | 0.26% | -0.54% | 3.34% | 0.55% | 1.14% | 0.13% | 0.51% |
| Total Current Liabilities | 2.47M | 4.58M | 3.9M | 6.73M | 10.18M | 10.67M | 13.64M | 33.35M | 26.64M | 47.87M |
| Accounts Payable | 242K | 159K | 906K | 571K | 1.1M | 670K | 2.33M | 14.23M | 2.24M | 2.14M |
| Days Payables Outstanding | 35.73 | 22.78 | 16.85 | 6.85 | - | 8.64 | - | - | - | - |
| Short-Term Debt | 1.1M | 0 | 0 | 2.29M | 3.98M | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 1000K | 1000K | 0 | 1000K | 0 | 301K | 289K | 288K | 288K | 288K |
| Other Current Liabilities | 295K | 1.17M | 353K | 239K | 674K | 7.29M | 3.75M | 4.87M | 12.75M | 10.74M |
| Current Ratio | 4.75x | 0.93x | 13.31x | 9.71x | 2.92x | 12.14x | 14.68x | 12.73x | 18.26x | 15.43x |
| Quick Ratio | 4.68x | 0.91x | 13.31x | 9.71x | 2.92x | 12.14x | 14.68x | 12.93x | 18.26x | 15.43x |
| Cash Conversion Cycle | 48.54 | 43.71 | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 24K | 2.82M | 10.07M | 8.07M | 4.33M | 544K | 2.36M | 6.68M | 21.77M | 22.89M |
| Long-Term Debt | 0 | 2.82M | 9.92M | 8M | 4.33M | 0 | 0 | 4.64M | 20.2M | 20.58M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 24K | 0 | 152K | 66K | 0 | 544K | 1.21M | 1.17M | 989K | 2.02M |
| Total Liabilities | 2.49M | 4.58M | 13.97M | 14.8M | 14.51M | 11.22M | 15.99M | 40.03M | 48.4M | 70.76M |
| Total Debt | 1.1M | 1.04M | 9.92M | 10.3M | 8.3M | 455K | 520K | 5.26M | 21.05M | 21.09M |
| Net Debt | -9.73M | -2.3M | -37.52M | -22.31M | -16.54M | -45.44M | -41.78M | -150.32M | -81.78M | -78.5M |
| Debt / Equity | 0.11x | - | 0.26x | 0.20x | 0.53x | 0.00x | 0.00x | 0.01x | 0.05x | 0.03x |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | -79.34x | -131.66x | -69.27x | -37.90x | -50.27x | -217.28x | -26576.00x | -276.35x | -137.76x | -98.17x |
| Total Equity | 10.41M | -326K | 38.51M | 51.34M | 15.75M | 120.04M | 187.72M | 395.06M | 442.02M | 671.64M |
| Equity Growth % | 0.74% | -1.03% | 119.13% | 0.33% | -0.69% | 6.62% | 0.56% | 1.1% | 0.12% | 0.52% |
| Book Value per Share | 19.30 | -0.45 | 30.02 | 26.02 | 7.54 | 33.75 | 15.75 | 12.31 | 9.88 | 9.89 |
| Total Shareholders' Equity | 10.41M | -326K | 38.51M | 51.34M | 15.75M | 120.04M | 187.72M | 395.06M | 442.02M | 671.64M |
| Common Stock | 106K | 7K | 226K | 308K | 23K | 42K | 239K | 414K | 540K | 810K |
| Retained Earnings | -17.97M | -30.64M | -93.59M | -126.3M | -168.17M | -278.89M | -358.3M | -488.17M | -725.91M | -995.86M |
| Treasury Stock | 0 | -5.15M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -739K | 0 | -2.83M | -3K | 0 | -8K | -157K | -390K | 338K | -10K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | -6.9M | -7.23M | -28.17M | -26.84M | -36.06M | -29.78M | -54.58M | -93.84M | -184.17M | -232.32M |
| Operating CF Margin % | -2.72% | -2.17% | -7.04% | -3.2% | -8.08% | -28.36% | -18.42% | -52.96% | -586.53% | -769.27% |
| Operating CF Growth % | -2.12% | -0.05% | -2.9% | 0.05% | -0.34% | 0.17% | -0.83% | -0.72% | -0.96% | -0.26% |
| Net Income | -11.33M | -12.67M | -26.51M | -32.7M | -41.87M | -110.72M | -79.41M | -129.87M | -237.73M | -269.95M |
| Depreciation & Amortization | 184K | 189K | 308K | 281K | 288K | 239K | 120K | 255K | 522K | 540K |
| Stock-Based Compensation | 3.02M | 2.11M | 2.41M | 3.68M | 3.97M | 3.65M | 14.46M | 19.77M | 67.17M | 42.15M |
| Deferred Taxes | 0 | 868K | 0 | -416K | -432K | 56K | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 132K | 93K | 94K | 376K | 340K | 72.57M | 8.52M | 54K | -4.71M | -14.66M |
| Working Capital Changes | 1.1M | 2.18M | -4.47M | 1.94M | 1.65M | 4.43M | 1.72M | 15.96M | -9.43M | 9.6M |
| Change in Receivables | 694K | -130K | -1.44M | 1.43M | -84K | 99K | -451K | 349K | 0 | 102K |
| Change in Inventory | -8K | 123K | -50.9M | -57.8M | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 633K | 2.03M | -101K | -335K | 525K | -426K | 1.66M | 11.52M | -12.04M | -73K |
| Cash from Investing | -95K | -3K | 1.03M | -29.91M | 28.23M | -50.48M | -74.29M | -115.13M | -94.25M | -228.65M |
| Capital Expenditures | -123K | -3K | -246K | -445K | -84K | -42K | -338K | -797K | -898K | -511K |
| CapEx % of Revenue | 0.05% | 0% | 0.06% | 0.05% | 0.02% | 0.04% | 0.11% | 0.45% | 2.86% | 1.69% |
| Acquisitions | - | - | - | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 28K | 0 | 1.28M | -29.46M | 28.31M | -3K | 79K | 0 | 0 | 0 |
| Cash from Financing | 12.71M | -257K | 52.47M | 41.92M | 70K | 101.31M | 125.28M | 322.24M | 225.67M | 457.74M |
| Debt Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - | - | - | - |
| Other Financing | 50K | 76K | -1.43M | -2.61M | 0 | -6.22M | -5.93M | -18.63M | 9.41M | -20.92M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | -7.02M | -7.23M | -28.41M | -27.29M | -36.14M | -29.82M | -54.92M | -94.64M | -185.07M | -232.83M |
| FCF Margin % | -2.77% | -2.17% | -7.1% | -3.25% | -8.1% | -28.4% | -18.53% | -53.41% | -589.39% | -770.96% |
| FCF Growth % | -1.83% | -0.03% | -2.93% | 0.04% | -0.32% | 0.17% | -0.84% | -0.72% | -0.96% | -0.26% |
| FCF per Share | -13.01 | -10.03 | -22.15 | -13.83 | -17.30 | -8.38 | -4.61 | -2.95 | -4.14 | -3.43 |
| FCF Conversion (FCF/Net Income) | 0.61x | 0.57x | 1.06x | 0.82x | 0.86x | 0.27x | 0.69x | 0.72x | 0.77x | 0.86x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 293K | 0 | 1.82M |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | -138.14% | -251.37% | -138.86% | -72.79% | -124.81% | -163.07% | -51.61% | -44.57% | -56.8% | -48.48% |
| Return on Invested Capital (ROIC) | -1026.33% | - | -2007.97% | -165.27% | -222.91% | -224.33% | -54.23% | -51.57% | -63.09% | -47.05% |
| Gross Margin | 2.6% | 23.64% | -390.21% | -262.76% | 100% | -2595.62% | 100% | 100% | 100% | 100% |
| Net Margin | -446.34% | -379.8% | -662.3% | -389.97% | -938.65% | -10544.29% | -2680.16% | -7329.23% | -75711.46% | -89387.09% |
| Debt / Equity | 0.11x | - | 0.26x | 0.20x | 0.53x | 0.00x | 0.00x | 0.01x | 0.05x | 0.03x |
| Interest Coverage | -79.34x | -131.66x | -69.27x | -37.90x | -50.27x | -217.28x | -26576.00x | -276.35x | -137.76x | -98.17x |
| FCF Conversion | 0.61x | 0.57x | 1.06x | 0.82x | 0.86x | 0.27x | 0.69x | 0.72x | 0.77x | 0.86x |
| Revenue Growth | -41.25% | 31.48% | 19.96% | 109.49% | -46.8% | -76.46% | 182.19% | -40.2% | -82.28% | -3.82% |
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Collaboration Revenue | 7.37M | - | 735K | 3M | 1.8M | 300K | 300K |
| Collaboration Revenue Growth | - | - | - | 308.16% | -40.00% | -83.33% | 0.00% |
| Grant | - | - | 315K | - | - | - | - |
| Grant Growth | - | - | - | - | - | - | - |
| Milestone Payments | - | - | - | - | - | - | - |
| Milestone Payments Growth | - | - | - | - | - | - | - |
| Reimbursement Revenue | 3.68M | - | - | - | - | - | - |
| Reimbursement Revenue Growth | - | - | - | - | - | - | - |
Viridian Therapeutics, Inc. (VRDN) reported $70.8M in revenue for fiscal year 2024. This represents a 1507% increase from $4.4M in 2012.
Viridian Therapeutics, Inc. (VRDN) saw revenue decline by 3.8% over the past year.
Viridian Therapeutics, Inc. (VRDN) reported a net loss of $302.0M for fiscal year 2024.
Viridian Therapeutics, Inc. (VRDN) has a return on equity (ROE) of -48.5%. Negative ROE indicates the company is unprofitable.
Viridian Therapeutics, Inc. (VRDN) had negative free cash flow of $326.3M in fiscal year 2024, likely due to heavy capital investments.